Royalty Pharma Plc Stock Price Prediction
| RPRX Stock | USD 32.77 0.09 0.28% |
Momentum 76
Buy Stretched
Oversold | Overbought |
Quarterly Earnings Growth (0.68) | EPS Estimate Next Quarter 1.0667 | EPS Estimate Current Year 4.6707 | EPS Estimate Next Year 4.9843 | Wall Street Target Price 40.92 |
Using Royalty Pharma hype-based prediction, you can estimate the value of Royalty Pharma Plc from the perspective of Royalty Pharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Royalty Pharma using Royalty Pharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Royalty using crowd psychology based on the activity and movement of Royalty Pharma's stock price.
Royalty Pharma Short Interest
An investor who is long Royalty Pharma may also wish to track short interest. As short interest increases, investors should be becoming more worried about Royalty Pharma and may potentially protect profits, hedge Royalty Pharma with its derivative instruments, or be ready for some potential downside.
200 Day MA 28.1486 | Short Percent 0.033 | Short Ratio 2.84 | Shares Short Prior Month 16.1 M | 50 Day MA 31.3408 |
Royalty Pharma Plc Hype to Price Pattern
Investor biases related to Royalty Pharma's public news can be used to forecast risks associated with an investment in Royalty. The trend in average sentiment can be used to explain how an investor holding Royalty can time the market purely based on public headlines and social activities around Royalty Pharma Plc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Royalty Pharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Royalty Pharma.
Royalty Pharma Implied Volatility | 0.58 |
Royalty Pharma's implied volatility exposes the market's sentiment of Royalty Pharma Plc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Royalty Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Royalty Pharma stock will not fluctuate a lot when Royalty Pharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Royalty Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Royalty because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Royalty Pharma after-hype prediction price | USD 33.26 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Royalty contract
Based on the Rule 16, the options market is currently suggesting that Royalty Pharma Plc will have an average daily up or down price movement of about 0.0363% per day over the life of the 2025-04-17 option contract. With Royalty Pharma trading at USD 32.77, that is roughly USD 0.0119 . If you think that the market is fully incorporating Royalty Pharma's daily price movement you should consider acquiring Royalty Pharma Plc options at the current volatility level of 0.58%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Royalty |
Royalty Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Royalty Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Royalty Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Royalty Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Royalty Pharma Estimiated After-Hype Price Volatility
In the context of predicting Royalty Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Royalty Pharma's historical news coverage. Royalty Pharma's after-hype downside and upside margins for the prediction period are 31.36 and 35.16, respectively. We have considered Royalty Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Royalty Pharma is very steady at this time. Analysis and calculation of next after-hype price of Royalty Pharma Plc is based on 3 months time horizon.
Royalty Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Royalty Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Royalty Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Royalty Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.47 | 1.90 | 0.49 | 0.41 | 9 Events / Month | 11 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
32.77 | 33.26 | 1.50 |
|
Royalty Pharma Hype Timeline
Royalty Pharma Plc is at this time traded for 32.77. The entity has historical hype elasticity of 0.49, and average elasticity to hype of competition of -0.41. Royalty is projected to increase in value after the next headline, with the price projected to jump to 33.26 or above. The average volatility of media hype impact on the company the price is about 182.69%. The price jump on the next news is projected to be 1.5%, whereas the daily expected return is at this time at 0.47%. The volatility of related hype on Royalty Pharma is about 216.14%, with the expected price after the next announcement by competition of 32.36. The company reported the previous year's revenue of 2.26 B. Net Income was 1.33 B with profit before overhead, payroll, taxes, and interest of 1.53 B. Given the investment horizon of 90 days the next projected press release will be in about 9 days. Check out Royalty Pharma Basic Forecasting Models to cross-verify your projections.Royalty Pharma Related Hype Analysis
Having access to credible news sources related to Royalty Pharma's direct competition is more important than ever and may enhance your ability to predict Royalty Pharma's future price movements. Getting to know how Royalty Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Royalty Pharma may potentially react to the hype associated with one of its peers.
Royalty Pharma Additional Predictive Modules
Most predictive techniques to examine Royalty price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Royalty using various technical indicators. When you analyze Royalty charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Royalty Pharma Predictive Indicators
The successful prediction of Royalty Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Royalty Pharma Plc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Royalty Pharma based on analysis of Royalty Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Royalty Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Royalty Pharma's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Dividend Yield | 0.0193 | 0.0285 | 0.033 | 0.0362 | Price To Sales Ratio | 7.74 | 5.34 | 5.04 | 4.79 |
Story Coverage note for Royalty Pharma
The number of cover stories for Royalty Pharma depends on current market conditions and Royalty Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Royalty Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Royalty Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Royalty Pharma Short Properties
Royalty Pharma's future price predictability will typically decrease when Royalty Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Royalty Pharma Plc often depends not only on the future outlook of the potential Royalty Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Royalty Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 592.7 M | |
| Cash And Short Term Investments | 987.2 M |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.